Top Companies in the Intravenous Immunoglobulin Market
- Takeda Pharmaceutical Company Limited
- CSL Behring
- Grifols, S.A.
- Octapharma AG
- Kedrion Biopharma
- Biotest AG
- Sanquin Plasma Products
- ADMA Biologics, Inc.
- LFB S.A.
- Green Cross Corporation (GC Pharma)
- China Biologic Products Holdings, Inc.
- Shanghai RAAS Blood Products Co., Ltd.
- Bharat Serums and Vaccines Ltd.
- Kamada Ltd.
- Emergent BioSolutions
- SK Plasma Co., Ltd.
- Intas Pharmaceuticals Ltd.
- Corning Life Sciences
- Hualan Biological Engineering Inc.
- Bio Products Laboratory (BPL)
Market Growth
The global intravenous immunoglobulin market size is calculated at USD 17.12 billion in 2024, grew to USD 18.68 billion in 2025, and is projected to reach around USD 40.78 billion by 2034. The market is expanding at a CAGR of 9.14% between 2025 and 2034.
Intravenous Immunoglobulin Market Trends
Increasing Collaboration: Collaborations are made to access advanced technologies and expand their product portfolio, along with geographical presence.
- In August 2025, GC Biopharma announced that it signed a Memorandum of Understanding (MoU) with the Thai Red Cross Society to cooperate on workforce training for the manufacturing of plasma-derived medicinal products. This collaboration enables GC Biopharma to establish a plasma fractionation facility in Thailand.
FDA Approval: Regulatory agencies like the U.S. Food and Drug Administration (FDA) approve IVIG therapeutics for various disorders.
- In January 2024, Takeda Corporation announced that it received the U.S. FDA approval for its Gammagard Liquid 10% solution. It is the only IVIG therapy for multiple neuromuscular indications in the U.S. It is also used for the treatment of multifocal motor neuropathy as a maintenance therapy.
Value Chain Analysis - Intravenous Immunoglobulin Market
R&D
Research activities for IVIG include the development of innovative IVIG for a plethora of immunological and rare disorders.
Key Players: CSL Behring, Octapharma, and Grifols.
Formulation & Final Dosage Preparation
IVIGs are usually manufactured to prepare final liquid or lyophilized formulations to maintain sterility, integrity, and stability.
Key Players: Kedrion Biopharma, ADMA Biologics, and Takeda Pharmaceutical Company.
Clinical Trials & Regulatory Approvals
IVIG undergoes clinical trials after final preparation to assess its safety and efficacy against numerous disorders. Regulatory agencies approve an IVIG based on its human trials.
Key Players: Bio Products Laboratory, Grifols Therapeutics LLC, Octapharma
Distribution to Hospitals, Pharmacies
After an IVIG is approved for market use, it is distributed to hospitals and pharmacies in the respective countries where it is approved.
Patient Support & Services
Patient support & services refer to providing clinical support, administration services, and care coordination for patients receiving IVIG treatment.
Latest Announcement by Industry Leaders
Kristina Allikmets, Senior Vice President and Head of R&D for Takeda’s Plasma-Derived Therapies Business Unit, commented that the approval of Gammagard Liquid ERC reinforces the company’s commitment to supporting individualized treatment approaches for people with primary immunodeficiency. The company aims to prioritize reliable supply while offering a broad range of IVIG therapies to address varied patient needs.
Recent Developments in the Intravenous Immunoglobulin Market
- In May 2025, researchers from Circulate Health found from its first-of-its-kind clinical trial that therapeutic plasma exchange (TPE) combined with IVIG reduced biological age on average by 2.6 years. They studied changes in the epigenome, proteome, metabolome, glycome, and the immune system.
- In March 2025, Grifols announced positive results from its Phase 2/3 trial evaluating the efficacy and safety of Grifols’ IVIG to treat patients with post-polio syndrome (PPS). IVIG infusions could significantly improve physical performance in PPS patients.
Become a valued research partner with us, please feel free to contact us at sales@towardshealthcare.com
